Induction of doxorubicin-mediated apoptosis via thioredoxin reductase 1 RNAi in human colon cancer cells

[1]  L. Szekely,et al.  High levels of thioredoxin reductase 1 modulate drug-specific cytotoxic efficacy. , 2009, Free radical biology & medicine.

[2]  J. Harvey,et al.  H2AX phosphorylation as a genotoxicity endpoint. , 2009, Mutation research.

[3]  P. Jeggo,et al.  DNA double-strand breaks: their cellular and clinical impact? , 2007, Oncogene.

[4]  A. Holmgren,et al.  The thioredoxin system in cancer. , 2006, Seminars in cancer biology.

[5]  V. Gladyshev,et al.  Thioredoxin Reductase 1 Deficiency Reverses Tumor Phenotype and Tumorigenicity of Lung Carcinoma Cells* , 2006, Journal of Biological Chemistry.

[6]  Richard A. Miller,et al.  The thioredoxin reductase/thioredoxin system: Novel redox targets for cancer therapy , 2005, Cancer Biology & Therapy.

[7]  M. Brechbiel,et al.  Thioredoxin Reductase as a Potential Molecular Target for Anticancer Agents That Induce Oxidative Stress , 2004, Cancer Research.

[8]  Elias S. J. Arnér,et al.  Regulation of the mammalian selenoprotein thioredoxin reductase 1 in relation to cellular phenotype, growth, and signaling events. , 2004, Antioxidants & redox signaling.

[9]  Stephen J Kron,et al.  Histone H2AX Phosphorylation as a Predictor of Radiosensitivity and Target for Radiotherapy* , 2004, Journal of Biological Chemistry.

[10]  K. O’Neill,et al.  The neutral comet assay is sufficient to identify an apoptotic ‘window’ by visual inspection , 1996, Apoptosis.

[11]  Joon-Hyuk Choi,et al.  Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas. , 2002, Anticancer research.

[12]  M. Kruszewski,et al.  A modified neutral comet assay: elimination of lysis at high temperature and validation of the assay with anti-single-stranded DNA antibody. , 2002, Mutation research.

[13]  Elias S. J. Arnér,et al.  Physiological functions of thioredoxin and thioredoxin reductase. , 2000, European journal of biochemistry.

[14]  R. V. Vander Heide,et al.  Molecular basis of anthracycline-induced cardiotoxicity and its prevention. , 2000, Molecular genetics and metabolism.

[15]  Elias S. J. Arnér,et al.  Structure and mechanism of mammalian thioredoxin reductase: the active site is a redox-active selenolthiol/selenenylsulfide formed from the conserved cysteine-selenocysteine sequence. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[16]  V. Gladyshev,et al.  Redox Regulation of Cell Signaling by Selenocysteine in Mammalian Thioredoxin Reductases* , 1999, The Journal of Biological Chemistry.

[17]  D. Gewirtz,et al.  A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. , 1999, Biochemical pharmacology.

[18]  M. Kunkel,et al.  Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides. , 1998, Biochemical pharmacology.

[19]  N. Bachur,et al.  Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation. , 1977, Molecular pharmacology.

[20]  S. Siegel,et al.  Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. , 1976, Cancer research.